Plain language summary of the CheckMate 76K study results: nivolumab given after stage 2B/2C melanoma is removed by surgery
John M. Kirkwood(UPMC Hillman Cancer Center), Georgina V. Long(The University of Sydney), Paolo A. Ascierto(Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale"), Vanna Chiarion‐Sileni(Centre Hospitalier Universitaire Brugmann), Petr Arenberger(Charles University), Peter Mohr(Elbe Kliniken Stade-Buxtehude), Jeffrey S. Weber(NYU Langone Health), Christoph Höeller(Medical University of Vienna), Caroline Dutriaux(Centre Hospitalier Universitaire de Bordeaux), Maurice Lobo(Bristol-Myers Squibb (United States)), Jean‐Jacques Grob(Aix-Marseille Université), Piyush Durani(Bristol-Myers Squibb (United States)), Tarek Meniawy(St John of God Subiaco Hospital), Piotr Rutkowski(The Maria Sklodowska-Curie National Research Institute of Oncology), Carmen Loquai(Johannes Gutenberg University Mainz), Brian Gastman(Cleveland Clinic), G. Quéreux(Nantes Université), Jacek Mackiewicz(Poznan University of Medical Sciences), Michele Del Vecchio(Fondazione IRCCS Istituto Nazionale dei Tumori), Federico Campigotto(Bristol-Myers Squibb (United States)), Alexander M. Menzies(The University of Sydney)
Cited by 2
Related Papers
Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation
|New England Journal of Medicine|2011|7.7k
Nivolumab in Previously Untreated Melanoma without <i>BRAF</i> Mutation
|New England Journal of Medicine|2014|5.3k
Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: American Society of Clinical Oncology Clinical Practice Guideline
|Journal of Clinical Oncology|2018|3.7k
Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial
|The Lancet|2012|3k
Combined Vemurafenib and Cobimetinib in <i>BRAF</i> -Mutated Melanoma
|New England Journal of Medicine|2014|2k